NeoGenomics' Surge Sparks Volatility Amid Ongoing Losses

Strong recent returns clash with persistent unprofitability, shaping the next half‑year outlook

NEO NeoGenomics, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

NEO — NeoGenomics, Inc.

Healthcare · Medical - Diagnostics & Research $294.54M · Micro Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Moderate

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +10.1% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

0.4x P/B 351.8x EV/EBITDA

⚖️ Tier

Fair Value

📊 Beta 1.80 (High Volatility)

NeoGenomics, Inc. (NEO) is a specialty diagnostic services provider that leverages an asset‑heavy laboratory platform to deliver genomic and molecular testing for oncology, hematology and rare disease patients across the United States. The company differentiates itself through proprietary test panels and integrated informatics, enabling higher reimbursement rates than generic labs while maintaining a niche market focus. With $727 million in revenue growing 10.1% YoY but operating at a -9.1% margin, NeoGenomics balances moderate top‑line momentum against ongoing cost pressures. Its defensive, B2B/B2C client mix and modest pricing power support cash flow stability, yet the limited moat and high beta (1.80) underscore sensitivity to competitive and market volatility.

Revenue growth of 10.1% YoY reflects expanding adoption of precision‑medicine testing, but a -9.1% operating margin signals that scaling efficiencies have not yet offset the capital intensity of its laboratory network.
The company's product differentiation—proprietary assay panels and data analytics—provides moderate pricing power, allowing it to command premiums over commodity diagnostics while still facing competitive pressure from larger reference labs.
A high beta of 1.80 indicates amplified stock volatility relative to the market, driven by its micro‑cap size, limited moat, and exposure to reimbursement policy shifts in the healthcare sector.
Despite a fair‑value valuation, NeoGenomics' defensive positioning in oncology diagnostics offers resilience during economic downturns, yet the -14.9% net margin highlights the need for operational improvements before it can deliver sustainable earnings growth.

Equity Performance & Market Positioning

NeoGenomics, Inc. (NEO) — Stock Returns

Recent Performance

22.6%

1 Month

vs S&P +22.4

21.7%

3 Month

vs S&P +12.1

-10.1%

6 Month

vs S&P -17.9

-7.3%

YTD

vs S&P -15.2

47.7%

1 Year

vs S&P +24.0

NEO outperformed the S&P over the past month (+22.6% vs +22.4%) but the margin was razor‑thin, indicating that the recent rally is largely market‑driven rather than company‑specific.
The three‑month gain of +21.7% substantially beat the index (+12.1%), suggesting a short‑term catalyst—likely a positive earnings surprise or new contract win—that resonated with investors.
Despite a strong 1‑year return of +47.7%, the stock has underperformed the S&P over the YTD period (-7.3% vs -15.2%), highlighting volatility and the importance of timing for momentum trades.
The six‑month decline of -10.1% was less severe than the broader market’s -17.9% drop, showing relative resilience that may attract risk‑averse investors seeking defensive biotech exposure.

Long-Term Performance (Annualized)

-14.8%

3 Year

vs S&P -35.3

-23.2%

5 Year

vs S&P -35.2

2.0%

10 Year

vs S&P -11.4

15.7%

Full History

vs S&P +7.5

Over the past three years NEO posted an annualized loss of -14.8%, yet this outperformed the S&P's -35.3% decline, indicating that the company's fundamentals have been more resilient than the broader market.
The five‑year annualized return of -23.2% still beats the index's -35.2%, reflecting a slower erosion of shareholder value and suggesting that strategic initiatives (e.g., assay diversification) are mitigating downside risk.
A 10‑year annualized gain of +2.0% versus the S&P's -11.4% demonstrates that NEO has transitioned from a loss‑making phase to modest growth, likely due to scaling of its oncology testing platform and recurring revenue streams.
The full‑history annualized return of +15.7%, more than double the S&P's +7.5%, signals long‑term compounding benefits from the company's niche positioning in precision medicine.

Highlight

NEO's 1‑year performance (+47.7%) more than double the S&P's +24.0% underscores a sustained growth narrative, likely driven by expanding test volumes and higher reimbursement rates, which could justify a premium valuation relative to peers.

Watch Out

NEO's long‑term negative returns over 3‑ and 5‑year horizons (-14.8% and -23.2%) reveal that growth is not yet sufficient to offset earnings volatility; a slowdown in test adoption or reimbursement pressure could deepen losses, potentially dragging the stock below its historical average return of +15.7%.

Equity Performance & Market Positioning

NeoGenomics, Inc. (NEO) — Risk & Smart Money

Risk Profile

59.6%

Volatility (20D)

1.81

Beta

0.73

Sharpe Ratio

-45.6%

Max Drawdown (1Y)

81

RSI (14)

69%

52-Week Range

A beta of 1.8 indicates NeoGenomics moves roughly 80% more than the market, amplifying both upside and downside in volatile environments.
The Sharpe ratio of 0.7 suggests modest risk‑adjusted returns; the stock’s excess return over the risk‑free rate is only 70% of its volatility, highlighting limited compensation for its high beta.
A maximum drawdown of -45.6% reveals that investors have endured nearly half‑price losses during past market stress, underscoring vulnerability to sharp corrections.
The RSI at 81.1 places the stock in overbought territory, implying a heightened probability of short‑term price pullbacks as momentum wanes.

Smart Money Positioning

521.3%

Institutional Ownership

+10.0% QoQ

18.75

Insider Buy/Sell

Institutional ownership stands at 521.34 million shares, reflecting strong confidence from large investors and providing liquidity support during market dips.
Institutions added nearly 10% of their holdings in the latest reporting period (Inst Change: +9.99%), signaling fresh capital inflow and a bullish view on near‑term catalysts.
Insider buying outweighs selling with a net buy‑sell ratio of 18.75, suggesting that management believes the current valuation is discounted relative to intrinsic value.
The 52‑week price range of $68.5 indicates the stock has rallied significantly from its lows, yet still trades below its recent highs, offering potential upside for smart money seeking a pullback entry.

Watch Out

Smart money’s optimism may be overstretched: the combined effect of an overbought RSI (81.1) and a 45.6% max drawdown means that if earnings or guidance disappoint, institutional positions could unwind rapidly, potentially accelerating a price correction of 10‑15% in the short term.

Revenue, Earnings & Margin History

NeoGenomics, Inc. (NEO) — Revenue & Growth

Revenue & Growth

Revenue of $727 M grew 10.1% YoY, outpacing the biotech average ~5%, indicating that NeoGenomics is successfully expanding its test menu and geographic footprint.
The three‑year CAGR of 12.6% demonstrates consistent top‑line acceleration, suggesting that recent acquisitions and payer contracts are translating into durable growth rather than a one‑off boost.
EPS remains negative at $‑4.20, reflecting ongoing investment in infrastructure and high share‑based compensation; the gap between revenue growth (10%) and earnings erosion underscores a near‑term profitability lag.
R&D intensity of 5.1% of revenue is modest for a diagnostics firm, implying that most growth is driven by commercial expansion rather than costly product development pipelines.

Highlight

The 12.6% three‑year CAGR signals a robust, compounding growth trajectory that can support future scale economies and justify premium valuation multiples relative to slower‑growing peers.

Margin Evolution

Gross margin sits at 38.8%, comfortably above the industry median of ~33%, reflecting strong pricing power on specialized molecular tests.
Operating margin is negative (-9.1%) due to elevated SG&A and share‑based compensation, indicating that operating efficiencies have not kept pace with revenue expansion.
Net margin of -14.9% highlights a sizable gap between cash generation and profitability; however, free cash flow is only slightly negative at -3.0% of revenue, suggesting the company is nearing breakeven on cash basis.
SBC expense represents 5.7% of revenue, a drag that could be mitigated by aligning incentive structures with long‑term earnings targets to improve margin trajectory.

Watch Out

The negative operating margin of -9.1% poses a risk: if SG&A costs continue to grow faster than revenue (e.g., >12% YoY), the company may require additional financing, diluting shareholders and pressuring valuation.

Revenue, Earnings & Margin History

NeoGenomics, Inc. (NEO) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+12.6%

5Y

+10.4%

💰 EPS

Revenue of $727 M grew 10.1% YoY, outpacing the biotech average ~5%, indicating that NeoGenomics is successfully expanding its test menu and geographic footprint.
The three‑year CAGR of 12.6% demonstrates consistent top‑line acceleration, suggesting that recent acquisitions and payer contracts are translating into durable growth rather than a one‑off boost.
EPS remains negative at $‑4.20, reflecting ongoing investment in infrastructure and high share‑based compensation; the gap between revenue growth (10%) and earnings erosion underscores a near‑term profitability lag.
R&D intensity of 5.1% of revenue is modest for a diagnostics firm, implying that most growth is driven by commercial expansion rather than costly product development pipelines.

Profitability & Return on Capital

NeoGenomics, Inc. (NEO) — DuPont & Efficiency

DuPont Decomposition (2025)

-12.9%

ROE

=

-14.9%

Net Margin

×

0.53x

Asset Turnover

×

1.6x

Eq. Multiplier

The sharp decline in ROE from -1.1% to -12.9% is driven primarily by a deteriorating net profit margin, which fell from -2.5% to -14.9%, indicating that operating losses are now consuming a larger share of revenue.
Asset turnover doubled from 0.27x to 0.53x, showing that the company is generating more sales per dollar of assets, but this improvement is insufficient to offset the margin collapse and thus worsens overall ROE.
The equity multiplier rose modestly from 1.55x to 1.63x, reflecting a slight increase in financial leverage; however, higher leverage amplifies the impact of negative earnings on shareholders' return.
Combined, the negative profit margin and rising leverage mean that each additional dollar of equity is now eroding value rather than creating it, signaling a fundamental profitability weakness.

Highlight

The 12-percentage-point swing in net profit margin to -14.9% is the dominant driver of the ROE plunge, underscoring that operating performance—not capital structure—is the core issue for investors.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	-12.9	-14.9	0.53	1.63	-5.2	-5.2	-7.9
2024	-8.7	-11.9	0.40	1.82	-6.9	-6.9	-4.8
2023	-9.3	-14.9	0.35	1.79	-6.8	-6.8	-5.2
2022	-14.5	-28.3	0.29	1.74	-9.6	-9.6	-8.3
2021	-0.8	-1.7	0.26	1.69	-6.7	-6.7	-0.4
2020	0.6	0.9	0.45	1.42	-1.6	-1.5	0.4
2019	1.6	2.0	0.58	1.40	2.0	2.0	1.1
2018	0.8	1.0	0.55	1.58	2.3	2.3	0.5
2017	-0.2	-0.2	0.70	1.67	0.9	0.9	-0.1
2016	-3.3	-2.5	0.72	1.81	0.9	0.9	-1.8
2015	-1.1	-2.5	0.27	1.55	-1.7	-1.7	-0.7

ROIC is negative 5.2%, indicating that the firm’s invested capital is not generating sufficient returns to cover its cost of capital, a red flag for value creation.
Despite an improved asset turnover, the cash conversion cycle has stretched to 84 days, suggesting slower collections and higher inventory or receivable balances that tie up cash.
The modest rise in the equity multiplier (1.55→1.63) does not translate into better capital efficiency because earnings are negative, resulting in a net erosion of shareholder value per dollar deployed.
Operating expenses have outpaced revenue growth, eroding margins and further depressing ROIC, which signals that cost discipline is lacking.

Watch Out

The 84‑day cash conversion cycle represents roughly $45 million of working capital locked up (based on average daily sales), increasing liquidity risk and limiting the company's ability to fund growth without external financing.

Profitability & Return on Capital

NeoGenomics, Inc. (NEO) — ROIC & Cash Conversion

Return on Invested Capital

Current-5.2%

Mean-2.9%

Min-9.6%

Max2.3%

Range11.9pp

Cash Conversion Cycle

Current84d

Mean87d

Min54d

Max131d

ROIC is negative 5.2%, indicating that the firm’s invested capital is not generating sufficient returns to cover its cost of capital, a red flag for value creation.
Despite an improved asset turnover, the cash conversion cycle has stretched to 84 days, suggesting slower collections and higher inventory or receivable balances that tie up cash.
The modest rise in the equity multiplier (1.55→1.63) does not translate into better capital efficiency because earnings are negative, resulting in a net erosion of shareholder value per dollar deployed.
Operating expenses have outpaced revenue growth, eroding margins and further depressing ROIC, which signals that cost discipline is lacking.

Profitability & Return on Capital

NeoGenomics, Inc. (NEO) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

23d

Inventory Days

+

80d

Receivables Days

+

82d

Fixed Asset Days

≈

682d

Total Asset Days

(0.53x turn)

Cash Conversion Cycle (2025)

23d

Inventory Days

+

80d

Receivables Days

−

19d

Payables Days

=

84d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	682	23	80	82	19	84
2024	905	26	83	96	21	88
2023	1037	25	81	113	21	85
2022	1246	28	86	142	23	90
2021	1409	29	85	160	22	91
2020	812	42	88	125	35	94
2019	633	25	85	81	34	76
2018	666	21	101	80	43	79
2017	522	20	92	55	28	84
2016	504	17	83	51	46	54
2015	1346	33	179	126	81	131

The sharp decline in ROE from -1.1% to -12.9% is driven primarily by a deteriorating net profit margin, which fell from -2.5% to -14.9%, indicating that operating losses are now consuming a larger share of revenue.
Asset turnover doubled from 0.27x to 0.53x, showing that the company is generating more sales per dollar of assets, but this improvement is insufficient to offset the margin collapse and thus worsens overall ROE.
The equity multiplier rose modestly from 1.55x to 1.63x, reflecting a slight increase in financial leverage; however, higher leverage amplifies the impact of negative earnings on shareholders' return.
Combined, the negative profit margin and rising leverage mean that each additional dollar of equity is now eroding value rather than creating it, signaling a fundamental profitability weakness.

Balance Sheet & Cash Flow Health

NeoGenomics, Inc. (NEO) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$1360M	$523M	$837M	$472M	$313M	$160M	$376M	$88M
2024	$1638M	$736M	$902M	$605M	$238M	$367M	$596M	$301M
2023	$1681M	$740M	$942M	$612M	$269M	$342M	$597M	$96M
2022	$1740M	$742M	$998M	$611M	$348M	$263M	$605M	$90M
2021	$1870M	$762M	$1108M	$613M	$296M	$317M	$682M	$87M
2020	$988M	$294M	$694M	$218M	$-10M	$229M	$449M	$73M
2019	$710M	$202M	$507M	$133M	$-40M	$173M	$291M	$64M
2018	$505M	$185M	$320M	$112M	$102M	$10M	$104M	$61M
2017	$343M	$138M	$206M	$105M	$93M	$13M	$85M	$35M
2016	$337M	$151M	$187M	$106M	$94M	$13M	$79M	$60M
2015	$368M	$130M	$238M	$71M	$48M	$23M	$99M	$40M

Liquidity & Solvency

6/9

Piotroski F-Score

Moderate

0.5

Altman Z-Score

Distress

The current ratio of 4.26 indicates that NeoGenomics holds more than four times the short‑term assets needed to cover its liabilities, providing a sizable buffer against working‑capital shocks and signaling strong liquidity.
A debt‑to‑equity ratio of 0.56 reflects a conservative capital structure; roughly $0.56 of debt for every dollar of equity, which limits financial risk and leaves ample capacity for future borrowing if needed.
Interest coverage is -17.61, meaning the company’s earnings before interest and taxes are insufficient to cover interest expense, highlighting that current operations generate negative operating profit relative to financing costs.
Free cash flow as a percentage of revenue is -2.99%, indicating modest cash burn; while not yet alarming, it suggests the firm must rely on external financing or operational improvements to turn cash generation positive.

Balance Sheet & Cash Flow Health

NeoGenomics, Inc. (NEO) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks
2025	$5M	$-12M	$-200M	$-27M	$-22M
2024	$7M	$13M	$5M	$-41M	$-34M
2023	$-2M	$77M	$5M	$-29M	$-31M
2022	$-66M	$1M	$12M	$-31M	$-97M
2021	$-27M	$-632M	$725M	$-64M	$-91M
2020	$1M	$-159M	$236M	$-29M	$-28M
2019	$23M	$-20M	$159M	$-20M	$3M
2018	$45M	$-140M	$92M	$-14M	$30M	$-50M
2017	$18M	$-14M	$-4M	$-14M	$4M
2016	$21M	$-7M	$-26M	$-8M	$14M	$-55M
2015	$6M	$-75M	$58M	$-2M	$4M

Cash Flow Trends

A Piotroski score of 6/9 places NeoGenomics in the upper tier of financially healthy firms, reflecting solid profitability, leverage reduction, and operating efficiency trends.
The Altman Z‑score of 0.53 falls well below the distress threshold of 1.8, signaling a high probability of bankruptcy within two years if current conditions persist.
Operating cash flow to net income ratio of -0.05 reveals that earnings are not being converted into cash; instead, each dollar of profit is accompanied by a five‑cent cash outflow, undermining the quality of reported earnings.

Balance Sheet & Cash Flow Health

NeoGenomics, Inc. (NEO) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski score of 6/9 places NeoGenomics in the upper tier of financially healthy firms, reflecting solid profitability, leverage reduction, and operating efficiency trends.
The Altman Z‑score of 0.53 falls well below the distress threshold of 1.8, signaling a high probability of bankruptcy within two years if current conditions persist.
Operating cash flow to net income ratio of -0.05 reveals that earnings are not being converted into cash; instead, each dollar of profit is accompanied by a five‑cent cash outflow, undermining the quality of reported earnings.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +47.7%

vs S&P +24.0pp

Revenue 3Y CAGR

▲ +12.6%

5Y: +10.4%

Net Margin

-14.9%

▲ 3Y ago: -28.3%

ROIC

-5.2%

▲ 3Y ago: -9.6%

FCF Margin

-3.0%

▲ 3Y ago: -19.0%

Piotroski

6/9

Moderate

NeoGenomics delivered a stellar 47.7% total return over the past year, outpacing the S&P 500 by roughly 24 percentage points, but that performance is built on an exceptionally volatile price profile (59.6% volatility) and a high beta of 1.81, indicating sensitivity to market swings. Revenue grew 10.1% YoY to $727 million and has compounded at a 12.6% three‑year rate, yet the company remains unprofitable with operating margins of -9.1% and net margins of -14.9%, driving EPS down to -$4.20. The balance sheet shows ample liquidity (current ratio 4.26) but weak cash conversion (free‑cash‑flow margin –3.0% and OCF/NI –4.8%), a modest leverage profile (D/E 0.56) and an Altman Z‑score of only 0.5, flagging heightened distress risk. Together, robust short‑term price appreciation is underpinned by top‑line growth but offset by persistent losses, thin cash generation, and a precarious solvency outlook, making the investment thesis contingent on turning profitability around.

✅ Strengths

Revenue expansion of 10.1% YoY to $727 M and a 12.6% three‑year CAGR demonstrates demand for NeoGenomics' testing services, supporting the case for continued top‑line momentum.
The current ratio of 4.26 indicates strong short‑term liquidity, providing a cushion to meet obligations despite ongoing losses.
Institutional ownership at 521.3% (relative to float) reflects significant confidence from large investors, which can stabilize share price and provide support during volatility.

⚠️ Risks

Operating margin of -9.1% and net margin of -14.9% reveal deep loss generation; without a clear path to profitability, cash burn may accelerate.
Free‑cash‑flow margin of -3.0% and OCF/NI ratio of -4.8% show that operating cash flow is insufficient to cover earnings, risking liquidity strain if revenue growth slows.
Altman Z‑score of 0.5 signals a high probability of financial distress, suggesting the company could face solvency issues if it cannot improve earnings or raise capital.

NEO

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.